Trial Profile

Single-center, randomized, open-label, single-dose, two-period, two-crossover bioequivalence study in fasting and fed states

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary)
Indications Biliary cancer; Breast cancer; CNS cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Kaposi's sarcoma; Liver cancer; Malignant melanoma; Malignant thymoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

27 Jul 2022 New trial record
01 Jul 2022 Results published in the Expert Opinion on Investigational Drugs

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com